孟鲁司特+丙酸氟替卡松与丙酸氟替卡松治疗儿童咳嗽变异性哮喘:成本-效用分析

IF 1.3 4区 医学 Q3 ALLERGY
Jefferson Antonio Buendía, Diana Guerrero Patino, Juan Antonio Buendia Sanchez
{"title":"孟鲁司特+丙酸氟替卡松与丙酸氟替卡松治疗儿童咳嗽变异性哮喘:成本-效用分析","authors":"Jefferson Antonio Buendía, Diana Guerrero Patino, Juan Antonio Buendia Sanchez","doi":"10.1080/02770903.2025.2546348","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The treatment of cough variant asthma is the same as for asthma in general. Recent evidence suggests montelukast (Mon) + fluticasone propionate (Flu) reduced cough recurrence regarding Flu in monotherapy. For health insurers whether this extra benefit offered by this combination of Flu is compensated by this additional cost compared to monotherapy with Flu. This study aims to evaluate the cost-utility of Montelukast (Mon) and Fluticasone Propionate (Flu) versus Flu monotherapy in children with Cough variant asthma in Colombia.</p><p><strong>Materials and methods: </strong>We simulated a hypothetical cohort of 10,000 pediatric patients diagnosed with cough variant asthma, reflecting the typical clinical profile in Colombia .A probabilistic Markov model was created to estimate the cost and quality-adjusted life-years (QALYs) of patients with cough variant asthma. Cost-effectiveness was evaluated at a willingness-to-pay (WTP) value of US$5180. This analysis used quality-adjusted life years (QALYs) and costs from a third-payer perspective over a 5-year time horizon.</p><p><strong>Results: </strong>The combination of Mon and Flu is not cost-effective since the incremental cost-utility ratio is greater than the willingness to pay per QALY in Colombia (USD 55,547 vs USD 5,180). The cost of Montelukast has the greatest influence on cost effectiveness, if the cost per dose of montelukast 5mg is less than US$0.034, the combination of Mon and Flu will be cost-effective at WTP of US$5180.</p><p><strong>Conclusion: </strong>The combination of Montelukast and Fluticasone Propionate is not cost-effective for the management of cough variant asthma in children in Colombia, given the current WTP threshold. To enhance the cost-effectiveness of this combination therapy, efforts should focus on reducing the price of Montelukast and further optimizing its clinical use.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-10"},"PeriodicalIF":1.3000,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Montelukast + fluticasone propionate vs. fluticasone propionate in the treatment of cough variant asthma in children: Cost-utility analysis.\",\"authors\":\"Jefferson Antonio Buendía, Diana Guerrero Patino, Juan Antonio Buendia Sanchez\",\"doi\":\"10.1080/02770903.2025.2546348\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The treatment of cough variant asthma is the same as for asthma in general. Recent evidence suggests montelukast (Mon) + fluticasone propionate (Flu) reduced cough recurrence regarding Flu in monotherapy. For health insurers whether this extra benefit offered by this combination of Flu is compensated by this additional cost compared to monotherapy with Flu. This study aims to evaluate the cost-utility of Montelukast (Mon) and Fluticasone Propionate (Flu) versus Flu monotherapy in children with Cough variant asthma in Colombia.</p><p><strong>Materials and methods: </strong>We simulated a hypothetical cohort of 10,000 pediatric patients diagnosed with cough variant asthma, reflecting the typical clinical profile in Colombia .A probabilistic Markov model was created to estimate the cost and quality-adjusted life-years (QALYs) of patients with cough variant asthma. Cost-effectiveness was evaluated at a willingness-to-pay (WTP) value of US$5180. This analysis used quality-adjusted life years (QALYs) and costs from a third-payer perspective over a 5-year time horizon.</p><p><strong>Results: </strong>The combination of Mon and Flu is not cost-effective since the incremental cost-utility ratio is greater than the willingness to pay per QALY in Colombia (USD 55,547 vs USD 5,180). The cost of Montelukast has the greatest influence on cost effectiveness, if the cost per dose of montelukast 5mg is less than US$0.034, the combination of Mon and Flu will be cost-effective at WTP of US$5180.</p><p><strong>Conclusion: </strong>The combination of Montelukast and Fluticasone Propionate is not cost-effective for the management of cough variant asthma in children in Colombia, given the current WTP threshold. To enhance the cost-effectiveness of this combination therapy, efforts should focus on reducing the price of Montelukast and further optimizing its clinical use.</p>\",\"PeriodicalId\":15076,\"journal\":{\"name\":\"Journal of Asthma\",\"volume\":\" \",\"pages\":\"1-10\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-08-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Asthma\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/02770903.2025.2546348\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Asthma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/02770903.2025.2546348","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

摘要

简介:咳嗽变异性哮喘的治疗方法与一般哮喘相同。最近的证据表明孟鲁司特(Mon) +丙酸氟替卡松(Flu)单药治疗可减少流感患者咳嗽复发。对于健康保险公司来说,与流感单一疗法相比,这种流感联合疗法带来的额外好处是否会被额外的费用所补偿。本研究旨在评估孟鲁司特(Mon)和丙酸氟替卡松(Flu)与流感单药治疗哥伦比亚咳嗽变异性哮喘儿童的成本-效用。材料和方法:我们模拟了1万名诊断为咳嗽变异性哮喘的儿童患者的假设队列,反映了哥伦比亚的典型临床概况,并创建了一个概率马尔可夫模型来估计咳嗽变异性哮喘患者的成本和质量调整生命年(QALYs)。成本效益评估的支付意愿(WTP)值为5180美元。该分析使用了质量调整生命年(QALYs)和第三方付款人在5年时间范围内的成本。结果:Mon和Flu联合治疗不具有成本效益,因为在哥伦比亚,增量成本效用比大于每个QALY的支付意愿(55,547美元对5,180美元)。孟鲁司特的成本对成本效益的影响最大,如果孟鲁司特5mg每剂的成本低于0.034美元,那么Mon和Flu联合使用的成本效益为5180美元。结论:考虑到目前的WTP阈值,孟鲁司特联合丙酸氟替卡松治疗哥伦比亚儿童咳嗽变异性哮喘不具有成本效益。为了提高这种联合治疗的成本效益,应重点降低孟鲁司特的价格,并进一步优化其临床应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Montelukast + fluticasone propionate vs. fluticasone propionate in the treatment of cough variant asthma in children: Cost-utility analysis.

Introduction: The treatment of cough variant asthma is the same as for asthma in general. Recent evidence suggests montelukast (Mon) + fluticasone propionate (Flu) reduced cough recurrence regarding Flu in monotherapy. For health insurers whether this extra benefit offered by this combination of Flu is compensated by this additional cost compared to monotherapy with Flu. This study aims to evaluate the cost-utility of Montelukast (Mon) and Fluticasone Propionate (Flu) versus Flu monotherapy in children with Cough variant asthma in Colombia.

Materials and methods: We simulated a hypothetical cohort of 10,000 pediatric patients diagnosed with cough variant asthma, reflecting the typical clinical profile in Colombia .A probabilistic Markov model was created to estimate the cost and quality-adjusted life-years (QALYs) of patients with cough variant asthma. Cost-effectiveness was evaluated at a willingness-to-pay (WTP) value of US$5180. This analysis used quality-adjusted life years (QALYs) and costs from a third-payer perspective over a 5-year time horizon.

Results: The combination of Mon and Flu is not cost-effective since the incremental cost-utility ratio is greater than the willingness to pay per QALY in Colombia (USD 55,547 vs USD 5,180). The cost of Montelukast has the greatest influence on cost effectiveness, if the cost per dose of montelukast 5mg is less than US$0.034, the combination of Mon and Flu will be cost-effective at WTP of US$5180.

Conclusion: The combination of Montelukast and Fluticasone Propionate is not cost-effective for the management of cough variant asthma in children in Colombia, given the current WTP threshold. To enhance the cost-effectiveness of this combination therapy, efforts should focus on reducing the price of Montelukast and further optimizing its clinical use.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Asthma
Journal of Asthma 医学-过敏
CiteScore
4.00
自引率
5.30%
发文量
158
审稿时长
3-8 weeks
期刊介绍: Providing an authoritative open forum on asthma and related conditions, Journal of Asthma publishes clinical research around such topics as asthma management, critical and long-term care, preventative measures, environmental counselling, and patient education.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信